Back to News
Market Impact: 0.3
Wave Life Science Advance Liver-Focused SiRNA Program With GSK; Stock Up
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Wave Life Sciences' liver-focused RNA medicine candidate has advanced into GSK's development pipeline, triggering a $12 million milestone payment under the companies' research collaboration. The progression validates Wave's RNA platform and provides incremental non-dilutive funding, though the candidate remains in development.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
WVE0.72
More News
- Tencent leases 100,000 chips from Oracle for $7 bln- FT
- RAM supply set to worsen, says Micron, as CEO celebrates ‘much higher’ prices
- Why is Nidec stock plunging today?
- Why is Kioxia stock rallying today?
- Nidec Corp shares slump after auditor declines to sign off on earnings
- We're raising our Micron price target after an incredible quarter and robust guidance
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Capital IQ Alternatives for Research and Deal Work
- Research Workflows, Report Format Selection, and Interactive Synthesis